# Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06976944/  
OnCo record `nct06976944` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, paclitaxel / nab-paclitaxel and bevacizumab in triple-negative breast cancer, run by Yukinori Ozaki, now recruiting.

## Summary

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06976944 by Yukinori Ozaki, with a registry enrolment figure of 24 participants, started 2025-06-24 and due to reach its primary completion in 2029-09. Interventions recorded: Pembrolizumab; Paclitaxel; Bevacizumab. Conditions listed: Recurrent Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Participants must have recurred after treatment with an anti-PD-1/PD-L1 antibody administered as monotherapy or in combination with other ICIs or chemotherapies as a perioperative drug therapy for triple negative breast cancer". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: PRELUDE
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06976944
- Phase: 2
- Setting: Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent Triple-Negative Breast Cancer Who Received Perioperative Immunotherapy
- Sponsor: Yukinori Ozaki
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06976944: https://clinicaltrials.gov/study/NCT06976944

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06976944.json